NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it intends to offer senior notes to cover the cost of its $925 million acquisition of One Lambda.

Thermo Fisher has not yet placed a value on the notes it intends to sell, but in a filing with the US Securities and Exchange Commission it said the notes would be due in 2018 and 2023. Joint book-running managers for the notes offering are Goldman Sachs, JP Morgan Securities, and RBS Securities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.